SE9904505D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9904505D0
SE9904505D0 SE9904505A SE9904505A SE9904505D0 SE 9904505 D0 SE9904505 D0 SE 9904505D0 SE 9904505 A SE9904505 A SE 9904505A SE 9904505 A SE9904505 A SE 9904505A SE 9904505 D0 SE9904505 D0 SE 9904505D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pharmaceutical compositions
therapy
preparing
formula
Prior art date
Application number
SE9904505A
Other languages
English (en)
Swedish (sv)
Inventor
Lilian Alcaraz
Mark Furber
Timothy Luker
Michael Mortimore
Philip Thorne
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9904505A priority Critical patent/SE9904505D0/xx
Publication of SE9904505D0 publication Critical patent/SE9904505D0/xx
Priority to RU2002118213/04A priority patent/RU2002118213A/ru
Priority to EP00983632A priority patent/EP1240132B1/en
Priority to PL00357103A priority patent/PL357103A1/xx
Priority to US10/149,190 priority patent/US6720452B2/en
Priority to SK762-2002A priority patent/SK7622002A3/sk
Priority to CN00816771A priority patent/CN1407968A/zh
Priority to JP2001543496A priority patent/JP2003516382A/ja
Priority to CZ20021982A priority patent/CZ20021982A3/cs
Priority to IL14976200A priority patent/IL149762A0/xx
Priority to BR0016227-2A priority patent/BR0016227A/pt
Priority to MXPA02005668A priority patent/MXPA02005668A/es
Priority to NZ518985A priority patent/NZ518985A/en
Priority to PCT/SE2000/002418 priority patent/WO2001042194A1/en
Priority to AT00983632T priority patent/ATE263748T1/de
Priority to HU0300618A priority patent/HUP0300618A3/hu
Priority to CA002394236A priority patent/CA2394236A1/en
Priority to EEP200200295A priority patent/EE200200295A/xx
Priority to DE60009747T priority patent/DE60009747T2/de
Priority to AU20363/01A priority patent/AU2036301A/en
Priority to KR1020027007354A priority patent/KR20020060991A/ko
Priority to ARP000106417A priority patent/AR032139A1/es
Priority to CO00093169A priority patent/CO5261526A1/es
Priority to ZA200203834A priority patent/ZA200203834B/xx
Priority to IS6405A priority patent/IS6405A/is
Priority to NO20022727A priority patent/NO20022727L/no
Priority to HK02108042.9A priority patent/HK1046527A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9904505A 1999-12-09 1999-12-09 Novel compounds SE9904505D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9904505A SE9904505D0 (sv) 1999-12-09 1999-12-09 Novel compounds
KR1020027007354A KR20020060991A (ko) 1999-12-09 2000-12-01 아다만탄 유도체
NZ518985A NZ518985A (en) 1999-12-09 2000-12-01 Adamantane derivatives
AT00983632T ATE263748T1 (de) 1999-12-09 2000-12-01 Admantan-derivate
PL00357103A PL357103A1 (en) 1999-12-09 2000-12-01 Adamantane derivatives
US10/149,190 US6720452B2 (en) 1999-12-09 2000-12-01 Adamantane derivatives
SK762-2002A SK7622002A3 (en) 1999-12-09 2000-12-01 Adamantane derivatives
CN00816771A CN1407968A (zh) 1999-12-09 2000-12-01 金刚烷衍生物
JP2001543496A JP2003516382A (ja) 1999-12-09 2000-12-01 アダマンタン誘導体
CZ20021982A CZ20021982A3 (cs) 1999-12-09 2000-12-01 Deriváty adamantanu
IL14976200A IL149762A0 (en) 1999-12-09 2000-12-01 Adamantane derivatives
BR0016227-2A BR0016227A (pt) 1999-12-09 2000-12-01 Derivados de adamantano
MXPA02005668A MXPA02005668A (es) 1999-12-09 2000-12-01 Derivados de adamantano.
RU2002118213/04A RU2002118213A (ru) 1999-12-09 2000-12-01 Производные адамантана
PCT/SE2000/002418 WO2001042194A1 (en) 1999-12-09 2000-12-01 Adamantane derivatives
EP00983632A EP1240132B1 (en) 1999-12-09 2000-12-01 Adamantane derivatives
HU0300618A HUP0300618A3 (en) 1999-12-09 2000-12-01 Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
CA002394236A CA2394236A1 (en) 1999-12-09 2000-12-01 Adamantane derivatives
EEP200200295A EE200200295A (et) 1999-12-09 2000-12-01 Adamantaani derivaadid
DE60009747T DE60009747T2 (de) 1999-12-09 2000-12-01 Admantan-derivate
AU20363/01A AU2036301A (en) 1999-12-09 2000-12-01 Adamantane derivatives
ARP000106417A AR032139A1 (es) 1999-12-09 2000-12-04 Derivados de adamantano, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica, y usos de estos derivados para la fabricacion de medicamentos
CO00093169A CO5261526A1 (es) 1999-12-09 2000-12-06 Compuestos novedosos
ZA200203834A ZA200203834B (en) 1999-12-09 2002-05-14 Adamantane derivatives.
IS6405A IS6405A (is) 1999-12-09 2002-05-31 Adamantanafleiður
NO20022727A NO20022727L (no) 1999-12-09 2002-06-07 Adamantanderivater
HK02108042.9A HK1046527A1 (zh) 1999-12-09 2002-11-05 金剛烷衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904505A SE9904505D0 (sv) 1999-12-09 1999-12-09 Novel compounds

Publications (1)

Publication Number Publication Date
SE9904505D0 true SE9904505D0 (sv) 1999-12-09

Family

ID=20418060

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904505A SE9904505D0 (sv) 1999-12-09 1999-12-09 Novel compounds

Country Status (27)

Country Link
US (1) US6720452B2 (ko)
EP (1) EP1240132B1 (ko)
JP (1) JP2003516382A (ko)
KR (1) KR20020060991A (ko)
CN (1) CN1407968A (ko)
AR (1) AR032139A1 (ko)
AT (1) ATE263748T1 (ko)
AU (1) AU2036301A (ko)
BR (1) BR0016227A (ko)
CA (1) CA2394236A1 (ko)
CO (1) CO5261526A1 (ko)
CZ (1) CZ20021982A3 (ko)
DE (1) DE60009747T2 (ko)
EE (1) EE200200295A (ko)
HK (1) HK1046527A1 (ko)
HU (1) HUP0300618A3 (ko)
IL (1) IL149762A0 (ko)
IS (1) IS6405A (ko)
MX (1) MXPA02005668A (ko)
NO (1) NO20022727L (ko)
NZ (1) NZ518985A (ko)
PL (1) PL357103A1 (ko)
RU (1) RU2002118213A (ko)
SE (1) SE9904505D0 (ko)
SK (1) SK7622002A3 (ko)
WO (1) WO2001042194A1 (ko)
ZA (1) ZA200203834B (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) * 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1633401A1 (en) * 2003-05-29 2006-03-15 AstraZeneca AB A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
EP1776352A1 (en) * 2004-06-29 2007-04-25 Pfizer Products Inc. Method for preparing 5-[4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h[1,2,4]triazin-2-yl]-benzamide derivatives by deprotecting the hydroxyl-protected precursers
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
AU2005258924A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
KR100643514B1 (ko) * 2005-05-17 2006-11-23 (주)아모레퍼시픽 히드록시벤조산 아미드 화합물과 그 제조방법 및 이를함유하는 미백화장료 조성물
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
EA018036B1 (ru) 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
RU2010121763A (ru) 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
DE602009000550D1 (de) 2008-03-25 2011-02-24 Affectis Pharmaceuticals Ag Neuartige P2X7R-Antagonisten und ihre Verwendung
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
TW201309706A (zh) 2011-07-22 2013-03-01 Actelion Pharmaceuticals Ltd 作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物
KR101957843B1 (ko) * 2011-10-06 2019-03-14 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
CN104066737B (zh) 2012-01-20 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
TWI612034B (zh) 2012-12-12 2018-01-21 愛杜西亞製藥有限公司 作爲ｐ２ｘ７受體拮抗劑之吲哚羧醯胺衍生物
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
WO2014115078A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
WO2014115072A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
IL295328A (en) 2020-01-31 2022-10-01 Kumiai Chemical Industry Co Derived from 3-Alkoxy Benzoic Acid Amide, and causes pest control.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
CA2015473C (en) 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
WO1995004720A2 (en) 1993-08-10 1995-02-16 Black James Foundation Gastrin and cck receptor ligands
JPH10504525A (ja) 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド ガストリンとｃｃｋ拮抗薬
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SK13422001A3 (sk) * 1999-04-09 2002-05-09 Astrazeneca Ab Adamantánové deriváty
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
US6720452B2 (en) 2004-04-13
EP1240132B1 (en) 2004-04-07
KR20020060991A (ko) 2002-07-19
IS6405A (is) 2002-05-31
ZA200203834B (en) 2003-08-14
PL357103A1 (en) 2004-07-12
HK1046527A1 (zh) 2003-01-17
AU2036301A (en) 2001-06-18
CA2394236A1 (en) 2001-06-14
CO5261526A1 (es) 2003-03-31
NO20022727D0 (no) 2002-06-07
US20020193414A1 (en) 2002-12-19
HUP0300618A3 (en) 2003-12-29
CZ20021982A3 (cs) 2003-01-15
CN1407968A (zh) 2003-04-02
BR0016227A (pt) 2002-10-01
DE60009747T2 (de) 2005-04-28
HUP0300618A2 (hu) 2003-07-28
AR032139A1 (es) 2003-10-29
WO2001042194A1 (en) 2001-06-14
ATE263748T1 (de) 2004-04-15
RU2002118213A (ru) 2004-01-10
NZ518985A (en) 2004-02-27
MXPA02005668A (es) 2002-09-02
JP2003516382A (ja) 2003-05-13
NO20022727L (no) 2002-07-29
EE200200295A (et) 2003-08-15
DE60009747D1 (de) 2004-05-13
IL149762A0 (en) 2002-11-10
SK7622002A3 (en) 2003-01-09
EP1240132A1 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
SE9904505D0 (sv) Novel compounds
SE9904738D0 (sv) Novel compounds
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
IS6658A (is) Ný efnasambönd
SE0104140D0 (sv) Novel Compounds
PT1263724E (pt) Novos compostos
SE9901875D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
MY125978A (en) Admantane derivatives
SE9704546D0 (sv) Novel compounds
ATE300541T1 (de) Pyrazolopyridinderivate
NO20020282D0 (no) Nytt difenylpiperidinderivat
GB0109122D0 (en) Novel compounds
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0101038D0 (sv) Novel compounds
SE9902551D0 (sv) Novel compounds
MXPA02012426A (es) Compuestos nuevos.
SE0202693D0 (sv) Compounds
ATE274515T1 (de) Pyrazolopyridinderivate
SE0102058D0 (sv) New Salts II